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Abstract
Louse-borne relapsing fever (LBRF) borreliosis is caused by Borrelia recurrentis, and it is a deadly although treatable disease
that is endemic in the Horn of Africa but has epidemic potential. Research on LBRF has been severely hampered because
successful infection with B. recurrentis has been achieved only in primates (i.e., not in other laboratory or domestic animals).
Here, we present the first non-primate animal model of LBRF, using SCID (-B, -T cells) and SCID BEIGE (-B, -T, -NK cells)
immunocompromised mice. These animals were infected with B. recurrentis A11 or A17, or with B. duttonii 1120K3 as
controls. B. recurrentis caused a relatively mild but persistent infection in SCID and SCID BEIGE mice, but did not proliferate
in NUDE (-T) and BALB/c (wild-type) mice. B. duttonii was infectious but not lethal in all animals. These findings demonstrate
that the immune response can limit relapsing fever even in the absence of humoral defense mechanisms. To study the
significance of phagocytic cells in this context, we induced systemic depletion of such cells in the experimental mice by
injecting them with clodronate liposomes, which resulted in uncontrolled B. duttonii growth and a one-hundred-fold
increase in B. recurrentis titers in blood. This observation highlights the role of macrophages and other phagocytes in
controlling relapsing fever infection. B. recurrentis evolved from B. duttonii to become a primate-specific pathogen that has
lost the ability to infect immunocompetent rodents, probably through genetic degeneration. Here, we describe a novel
animal model of B. recurrentis based on B- and T-cell-deficient mice, which we believe will be very valuable in future research
on LBRF. Our study also reveals the importance of B-cells and phagocytes in controlling relapsing fever infection.
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Introduction
Bacteria of the genus Borrelia are spirochetes that cause either
Lyme disease or relapsing fever (RF). Borrelia species are
transferred from animals to humans by tick bites, with the single
exception of B. recurrentis, which is transmitted between humans by
the body louse Pediculus humanus humanus. The louse-borne disease
is not transmitted by the bite per se, but rather through
contamination of abraded skin by feces or coelomic fluid released
from lice that are crushed by scratching. P. humanus humanus is
strictly a human-specific parasite that lives on the body and in the
clothing of its host, and B. recurrentis has been found only in lice and
humans [1,2].
In most cases, louse-borne relapsing fever (LBRF) presents with
a sudden onset of fever (typically 38.7–41uC) and chills. The first
fever period lasts on average 5–7 days and is accompanied by
malaise, nausea, general aches, and enlargement of the spleen and
liver. Compared to tick-borne RF, LBRF usually involves fewer
relapses, but it results in far greater mortality, which can be as high
as 40% if left untreated but as low as 1%–5% when antibiotic
therapy is given. The Jarish-Herxheimer reaction and delayed
onset of antimicrobial therapy are associated with an elevated
mortality risk [1,2,3].
LBRF previously occurred worldwide in massive epidemics, the
latest of which were seen during the two world wars. Today, the
only endemic area is in the highlands of Ethiopia, and sporadic
outbreaks have been observed in Sudan, where the disease is
associated with natural disasters, famine, and refugee camps
[1,2,4,5,6]. Although B. recurrentis is currently found only in the
Horn of Africa, it can become established wherever there are
human body lice and thus it has a high potential to cause global
epidemics [7], especially today due to the massive political turmoil
in the Horn of Africa. A population of lice can increase by 11% a
day, which gives a clue as to just how rapidly an outbreak can
spread in places like refugee camps [1,8]. Therefore, LBRF may
be even more important now than it has been for decades.
Despite increasing epidemic potential and important scientific
progress such as the recent genome sequencing of B. recurrentis [9],
research is hampered by the lack of feasible animal models. In the
early 20th century, scientists attempted to infect commonly used
laboratory animals as well as several species of domestic and wild
animals, but only experiments using primates seemed to have been
successful [10]. Moreover, B. recurrentis was not isolated in vitro until
1994, when Cutler and coworkers [11] managed to grow a few
strains in BSK broth. That event paved the way for microbiolog-
ical and biochemical investigations, but the lack of an animal
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focused on host-pathogen interactions, as well as other experi-
ments that require an in vivo model system.
We used immunodeficient mouse strains to develop an animal
model of B. recurrentis infection that is more practical in all aspects
compared to a primate-based model. SCID mice carry the Prkdc
scid
mutation, which results in severe combined immunodeficiency due
to a defect in V(D)J recombination; this condition impairs the
animals’ ability to generate B- and T-cell antigen receptors, thus
leading to very low numbers of functional lymphocytes [12].
NUDE mice lack a thymus, and they have impaired T-cell
function due to the Foxn1
nu mutation [13], whereas the cells of
their innate immune system (monocytes, macrophages, natural
killer cells and neutrophils) and their complement system remain
functional. Mice with the BEIGE mutation (Lyst
bg) have defective
natural killer (NK) cells [14]. Hence, SCID BEIGE mice lack B-,
T-, and NK-cells.
Clodronate liposomes have been used extensively in infection
models to study the pathobiological effect of systemic depletion of
phagocytic cells (e.g., macrophages) and the immunological
importance of such cells in combating infection [15,16,17,18].
These liposomes are artificially prepared lipid vesicles that
encapsulate clodronate, and they can be injected intravenously
to attack phagocytic cells that are present in or in contact with the
blood (e.g., macrophages in the spleen and liver). The clodronate is
ingested by and accumulated within phagocytic cells, and after an
intracellular threshold concentration of the drug is exceeded, the
cells are irreversibly damaged and die by apoptosis, as described
elsewhere [19]. Still, it is important to remember that clodronate
does not eliminate all phagocytic cells, and that new phagocytes
will continuously appear as soon as the liposomes are consumed; in
other words, the phagocytic activity cannot be totally inhibited.
Free clodronate (i.e. released from dead macrophages) has a very
short half-life and is quickly removed from the circulation by the
renal system, furthermore it can not easily pass through cell
membranes and thus can not affect non-phagocytic cells [20].
By using animals deficient in various immune cells and inducing
systemic depletion of phagocytes, much can be learned about the
immune defense against RF borreliosis and host-pathogen
interactions. In the current investigation, we found that SCID
mice could support growth of B. recurrentis, which led to a low-
grade, persistent disease. Moreover, employing clodronate lipo-
somes to deplete phagocytic cells resulted in a one-hundred-fold
rise in the spirochete titers. Thus, in this paper we present the first
non-primate animal model for studies of LBRF. We also
characterize B. recurrentis infection and compare it with the closely
related species B. duttonii, which is virulent in wild-type mice and
has been studied extensively in mouse models [21,22].
Methods
Bacterial strains and growth
The two B. recurrentis strains A11 and A17 were isolated in
Ethiopia and were kindly provided by Sally Cutler, University of
East London. Isolation and characterization of these strains has
been described by other investigators [11]. B. duttonii 1120K3 was
kindly provided by Guy Baranton, Institute Pasteur. All bacteria
were cultured at 37uC in BSK-II medium supplemented with 10%
(v/v) rabbit serum and 1.4% (w/v) gelatin, as described elsewhere
[23]. The bacteria used in experiments had less than 10 passages
through animals or in vitro in our lab.
Animal infection
To create and validate a B. recurrentis non-primate animal model,
we injected 1610
6 B. duttonii, B. recurrentis A11, or B. recurrentis A17
subcutaneously (s.c.) into four 6-week-old male mice of each of the
following strains (all from Taconic, Denmark): BALB/c (BALB/
cAnNTac), BALB/c NUDE (C.Cg/AnNTac-Foxn1
nu NE9), SCID
(C.B-Igh-1
b/IcrTac-Prkdc
scid), and SCID BEIGE (C.B-Igh-1b/
GbmsTac-Prkdc
scid-Lyst
bg N7). The animals were kept in a filter
cabinet and given food and water ad libitum, with all maintenance
performed according to Swedish animal welfare guidelines. Tail
blood was collected daily, and bacteria in the samples were
counted by phase contrast microscopy during the first 20 days of
infection. SCID and SCID BEIGE mice infected with B. recurrentis
were kept until day 150 post infection (p.i.), and spirochetemia was
quantified weekly by microscopy. All animal experiments were
approved in advance by the Laboratory Animal Ethics Committee
of Umea ˚ University.
Depletion of phagocytic cells
Starting one day before infection and subsequently every fifth
day, an intravenous (i.v.) injection of 100 ml clodronate liposomes
in phosphate-buffered saline (PBS) was administered in the tail of
SCID BEIGE and BALB/c mice to deplete phagocytic cells
present in the blood and organs (e.g., spleen and liver); this was
done as described elsewhere [19]. Since the phagocytes might also
have ingested liposomes that contained PBS instead of clodronate,
which would have reduced the phagocytic efficiency, we gave mice
i.v. injections of 100 ml PBS as negative controls. The animals
were infected with either B. recurrentis A17 or B. duttonii 1120K3 five
days after the first clodronate injection.
Statistics
Spirochetemia (non-Gaussian) was analyzed by the Mann-
Whitney U-test, and the results are presented as medians with 25th
and 75th percentile bars to illustrate variance. Difference in spleen
weight was assessed by Student’s t-test.
Results
We conducted tests to determine whether any of the commercially
available immunodeficient mouse strains can support growth of B.
recurrentis. Initially, the two B. recurrentis strains A11 and A17, and B.
duttonii strain 1120K3 were inoculated into immunocompetent
Author Summary
Research on Borrelia recurrentis, the agent of louse-borne
relapsing fever (LBRF), has been hampered by the lack of a
feasible non-primate animal model. By using immuno-
compromised SCID mice deficient in B- and T-cells, we
were able to establish a stable, persistent B. recurrentis
infection with low spirochetemia. Furthermore, systemic
depletion of phagocytes by use of clodronate liposomes
increased the numbers of bacteria in blood, which
demonstrates the importance of both the humoral
response and phagocytosis in controlling relapsing fever
infection. Lice are favored by the conditions related to the
unfortunate turmoil and refugee camps prevailing in the
Horn of Africa, and hence LBRF is more important now
than it has been for several decades. The newly published
genome sequence of B. recurrentis and techniques to
genetically manipulate RF borreliae will be instrumental in
understanding its complex biology. We therefore believe
that our novel animal model will be a great asset that can
facilitate future studies of the infection biology of B.
recurrentis.
An Animal Model of B. recurrentis
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lacking B- and T-cells, and SCID BEIGE mice lacking B-, T-, and
NK-cells. As expected, only B. duttonii established detectable infection
i nt h eB A L B / cm i c e( F i g u r e1 A ) ,w h ich concurred with the results of
similar previous experiments [22,24]. The total B. duttonii spirochet-
emia did not differ significantlyb e t w e e nN U D Em i c ea n dB A L B / c
mice (Figure 1A–B), and neither the A11 nor the A17 B. recurrentis
strain caused detectable spirochetemia in BALB/c or NUDE mice,
indicating that T-cells are of minor importance for RF immune
defense. However, both the B. recurrentis strains did establish infection
in SCID and SCID BEIGE mice, although the spirochetemia was
about 200-fold lower than that caused by B. duttonii infection (Figures 1
C–D and 2). Due to the lack of antibodies, B. recurrentis spirochetemia
did not display a relapsing pattern. Instead, spirochete titers remained
fairly constant over time, and there were only minor fluctuations
between the mice, which were probably caused by individual,
biological variations in the host-pathogen interactions (Figure 2). Both
the A11 and A17 bacteria were persistent and remained at fairly low
levels in the blood (about 2610
5/ml) at least until day 150 post
infection. The A11 strain caused a significantly (p,0.01) milder
Figure 1. B. duttonii spirochetemia in mice. BALB/c (A), NUDE (B), SCID (C), and SCID BEIGE (D) mice. B. duttonii established infection in all four
mouse strains. Spirochetemia was significantly (p=0.02) higher in B-cell-deficient mice (C, D). No differences were observed between wild-type and
T-cell-deficient mice (A vs. B) or between SCID mice and NK-cell-deficient SCID BEIGE mice (C vs. D). Data are presented as medians with 25
th and 75
th
percentiles. Notice that the scales of the y-axes in this figure differ from those in Figures 2 and 4.
doi:10.1371/journal.pntd.0000522.g001
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by the A17 strain in both SCID and SCID BEIGE mice (Figure 2).
The animals behaved normally and showed no outer sign of disease,
and their weight pattern corresponded to what was seen in uninfected
animals (data not shown). To ascertain whether the passage through
SCID BEIGE mice rendered the bacteria capable of causing
spirochetemia in wild-type mice, we inoculated four BALB/c mice
with spirochetes obtained from two A11-infected and two A17-
infected animals. None of those four mice developed detectable
spirochetemia. The B. recurrentis A17 infection induced significant
(p,0.01) splenomegaly in SCID BEIGE mice. However, the spleens
were much smaller in B-cell- and T-cell-deficient mice than in wild-
type mice (Figure 3), which implies activation and multiplication of
splenic immune cells. Surprisingly, B. duttonii did not cause a lethal
infection in the B-cell-deficient animals, despite the indispensable role
of B-cells suggested by the antibody-mediated clearance of antigenic
variants in immunocompetent models (Figure 1C, D). Although both
B. recurrentis and B. duttonii spirochetemia were higher in B-cell-deficient
mice (p=0.02), which verifies significance of the B-cells, the disease
was kept under control by B-cell-independent mechanisms
(Figures 1C, D and 2).
Notably, we also found that clodronate-treated (i.e., phagocyte-
depleted) mice infected with B. duttonii were unable to restrict the
bacterial infection. These animals developed very high spirochet-
emia, which killed all the SCID BEIGE mice before day 8 p.i.
(Figure 4B). The pattern was similar in BALB/c mice, although
one single individ survived and managed to control the infection
(Figure 4A). B. recurrentis A17 also caused substantial spirochetemia
in clodronate-treated SCID BEIGE mice (Figure 4C), although
the level that was reached was about 10 times higher than the
spirochetemia induced by B. duttonii in untreated wild-type mice
(Figure 4A and 4C). However, B. recurrentis was unable to establish
infection in phagocyte-depleted BALB/c mice, which underlines
the significance of B-cells and possibly also T-cells.
Discussion
Several attempts have been made to establish B. recurrentis
infection in various animals, but, until now, only primate models
have been successful [10], which has severely hampered research
on LBRF. In the present study, we used mice deficient in T- and
B-cells and induced phagocyte depletion by administering
clodronate liposomes to create the first non-primate animal model
of LBRF infection. The results of our experiments show that B.
recurrentis could infect both SCID and SCID BEIGE mice. The two
B. recurrentis strains A11 and A17 caused moderate, persistent
infection in B- and T-cell-deficient SCID mice and B-, T- and
NK-cell-deficient SCID BEIGE mice (Figure 2), but did not
induce detectable spirochetemia in either wild-type BALB/c
Figure 2. B. recurrentis spirochetemia in SCID BEIGE and SCID mice. B. recurrentis established a relatively low-grade (compared to B. duttonii,
see Figure 1C, D), stable infection in SCID BEIGE and SCID mice, but not in BALB/c or NUDE animals. Strain A17 (panel A) caused a higher (p,0.01)
level of spirochetemia than did strain A11 (panel B). No difference in B. recurrentis spirochetemia was observed between SCID BEIGE and SCID mice.
Data are presented as medians with 25
th and 75
th percentiles.
doi:10.1371/journal.pntd.0000522.g002
Figure 3. Splenomegaly in infected mice. Although expansion of
B- and T-cells is the major cause of splenomegaly in wild-type animals,
SCID BEIGE mice infected with B. recurrentis A17 displayed significant
(p,0.01) splenomegaly,which indicates a T-, B-, and NK-cell-indepen-
dent immune response.
doi:10.1371/journal.pntd.0000522.g003
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strains we used were isolated from different LBRF patients in
Ethiopia [11] and had an estimated history of ,20 BSK passages.
Since RF spirochetes do not lose plasmids in vitro (which is the case
in Lyme Borrelia spirochetes), and they maintain infectivity even
after several passages in vitro [9,25], the two strains we chose to use
were probably well representative of B. recurrentis.
Despite the ability of RF spirochetes to evade the host humoral
response through antigenic variation, antibodies are definitely an
important part of immune defense against this disease [26,27].
This is also reflected by the present findings showing higher B.
duttonii spirochetemia and establishment of B. recurrentis infection in
the B-cell-deficient mice. Moreover, the interaction between the
humoral response and B. recurrentis seems to be somewhat different
than noted for other RF-inducing bacteria, since B. recurrentis
generally causes 0–4 relapses, whereas other African species cause
3–9, as reviewed by other researchers [1,2]. T-cells are apparently
less important, since we observed that B. duttonii spirochetemia was
equally high in wild-type BALB/c animals and the athymic, T-
cell-deficient NUDE mice (Figure 1A, B). Similar results have been
reported in experiments on both the RF agent B. turicatae and
Lyme borreliosis [28,29]. Furthermore, an investigation of
RAG2
2/2 and RAG2/IL-10
2/2 mice infected with B. turicatae
has suggested that NK-cells play an important role [30]. In
contrast, we found that SCID mice with the BEIGE mutation,
which causes NK-cell deficiency, showed the same levels of B.
recurrentis or B. duttonii spirochetemia as seen in SCID mice
(Figures 1C, D and 2). On the other hand, phagocyte depletion by
use of clodronate liposomes had a dramatic effect on both
spirochetemia and disease. B. duttonii infection was uncontrollable
in all animals but one, and even B. recurrentis reached spirochet-
emia of over 5610
8/ml. The apparent ‘‘relapses’’ in clodronate-
treated animals were not due to antigenic variation, but instead to
partial host recovery from the phagocytic depletion that was
repeated every fifth day (Figure 4A, C). Even between the two
peaks in B. recurrentis-infected mice, median spirochetemia never
receded below 8610
6/ml, which is a fairly high level (Figure 4C).
These results clearly illustrate that it is important for phagocytic
cells to be able to filter and to some extent also control spirochetes
in the blood, even in the absence of B- and T-cells. Furthermore,
experiments in vitro have indicated that B. recurrentis avoids
complement opsonization and phagocytosis by binding comple-
ment regulators such as factor H and by degrading C3b from its
surface in order to utilize ‘‘hijacked’’ host plasmin [31,32].
However, this remains to be convincingly demonstrated in vivo.
Despite all of these isolated findings, it is essential to bear in mind
that the immune system is a tightly connected web of cells and
signal molecules, and that removal of one cell type might have
other downstream effects on overall immunity.
The recent genome analysis performed by Lescot et al. [9]
revealed that B. recurrentis evolved from B. duttonii through extensive
genetic decay, probably involving loss of the genes mutS and recA,
which are important for DNA repair. Both of these species are
considered to be more or less specific to humans, and it has been
debated whether this is due to a restricted host infectivity range, or
simply to the fact that both the B. duttonii tick vector Ornithodorus
moubata moubata and the B. recurrentis louse vector P. humanus humanus
strongly prefer humans as a source of food. B. duttonii establishes
RF in wild-type laboratory mice and rats that is similar to the
human disease, and this spirochete has recently been found in
chickens and pigs raised in proximity to tick-infested human
dwellings in Tanzania [33], indicating a wider potential host range
than was previously believed. In short, B. duttonii can infect
different species of animals, but it is ecologically very restricted by
the host range of its vector. It might be assumed that B. recurrentis
should also be able to infect non-primate animal species, perhaps
even more severely than does B. duttonii, since in humans it is
basically a more pathogenic strain of B. duttonii. Interestingly, this
greater virulence seems to originate from the loss of a gene or
genes rather than the gain of novel genes [9], as has also been
described in other louse-borne infections, such as Rickettsia
prowazekii [34]. B. recurrentis has lost its ability to survive in hosts
other than humans, and the way this spirochete is transmitted (i.e.,
not by the louse bite but by fecal or hemolymph contamination of
abraded skin) is a somewhat unsophisticated strategy that suggests
a short evolutionary adaptation. It is tempting to speculate that the
lost capacity of B. recurrentis to infect non-primate animals may also
be a result of genomic decay. B. duttonii probably possesses
mechanisms for evading the immune defense of host animals,
which have disappeared in B. recurrentis during its rapid evolution
Figure 4. Effect of clodronate-induced macrophage depletion on spirochetemia. Mice were injected with clodronate liposomes in PBS to
deplete macrophages (and other phagocytic cells) in the blood and in organs in contact with the blood (e.g., the spleen and liver). PBS was used as a
negative control. The injections (indicated by black triangles) were given every fifth day, starting one day before infection. A. BALB/c mice infected
with B. duttonii developed very high spirochetemia, and all except one individual (dotted line) died at day 6 p.i. B. B. duttonii-infected SCID BEIGE mice
treated with clodronate developed uncontrolled spirochetemia, and they all died before day 8 p.i. Control SCID BEIGE and BALB/c mice injected with
PBS had much lower spirochetemia compared to their macrophage-depleted counterparts. C. SCID BEIGE mice treated with clodronate and infected
with B. recurrentis A17 developed high but not lethal spirochetemia. The maximum spirochetemia in any of the control SCID BEIGE and BALB/c mice
injected with PBS was 7.3610
6/ml. Even between the two peaks shown for the B. recurrentis-infected, clodronate-treated mice, the median
spirochetemia was never below 8610
6/ml. B. recurrentis was unable to establish detectable spirochetemia in macrophage-depleted BALB/c mice.
doi:10.1371/journal.pntd.0000522.g004
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host. Inasmuch as SCID mice are defective in B- and T-cell
production, they readily accept foreign cells and tissues without
rejection. Future experiments by our group should be aimed at
creating humanized SCID-hu mice that generate human immune
cells or carry stem-cell-producing human xenotransplants to
pinpoint the factors that restrict LBRF to humans. Such strategies
have been successfully applied in other human-specific infectious
diseases, as described by other investigators [35]. For instance,
SCID-hu mice with human B-cells may constitute a better model
of human B. recurrentis infection that can facilitate studies of aspects
such as antigenic variation that seems to be responsible for a
difference causing fewer relapses compared to tick-borne RF [2].
B. recurrentis was grown in vitro for the first time in 1994 [11],
which opened the door for microbiological and immunological
studies conducted in vitro [32,36]. In addition, the complete
genomes of B. recurrentis and B. duttonii were recently sequenced and
published for the first time [9], and the first site-specific genetic
manipulation of an RF agent was performed last year when the
variable tick protein was knocked out and reconstituted in B.
hermsii [37]. All of these achievements will definitely encourage
further development of genetic tools and facilitate molecular
biological investigations of RF. Here, we have described the first
non-primate animal model of LBRF, which we believe is the
fourth cornerstone needed to bring B. recurrentis research into the
21st century.
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